Italy has one of the highest prevalence rates of Hepatitis C Virus (HCV) infection in Europe, and HCV infection is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death. In light of this, Direct Acting Antiviral Agents (DAAs) would have a huge public health impact in Italy. A longitudinal prospective HCV cohort study known as PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali: Italian Platform for the Study of Viral Hepatitis Therapies) has been developed as a collaboration among the Istituto Superiore di Sanità (the National Institute of Public Health in Italy), the Italian Society for the Study of the Liver, the Italian Society for Infectious Diseases, and their more than 100 affiliated Clinical Centres. The cohort will consist of a representative sample of approximately 10,000 consecutive patients with chronic HCV liver disease with an expected follow-up of at least 10 years. The first round of enrolment began in May 2014; enrolment will be re-opened for three-month periods during subsequent years to catch the introduction of new DAAs.
PITER-HCV cohort study as part of the Italian platform for the study of viral hepatitis therapies
Di Gregorio, M;Massella, M;Rosato, S;Segala, D.Membro del Collaboration Group
;
2015
Abstract
Italy has one of the highest prevalence rates of Hepatitis C Virus (HCV) infection in Europe, and HCV infection is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death. In light of this, Direct Acting Antiviral Agents (DAAs) would have a huge public health impact in Italy. A longitudinal prospective HCV cohort study known as PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali: Italian Platform for the Study of Viral Hepatitis Therapies) has been developed as a collaboration among the Istituto Superiore di Sanità (the National Institute of Public Health in Italy), the Italian Society for the Study of the Liver, the Italian Society for Infectious Diseases, and their more than 100 affiliated Clinical Centres. The cohort will consist of a representative sample of approximately 10,000 consecutive patients with chronic HCV liver disease with an expected follow-up of at least 10 years. The first round of enrolment began in May 2014; enrolment will be re-opened for three-month periods during subsequent years to catch the introduction of new DAAs.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
